抗GBM肾炎 中国就医指南

Anti-glomerular basement membrane (anti-GBM) nephritis, also known as Goodpasture syndrome when accompanied by pulmonary hemorrhage, is a rare, life-threatening autoimmune disorder characterized by the production of pathogenic IgG autoantibodies targeting the non-collagenous domain (NC1) of the alpha-3 chain of type IV collagen in the glomerular and alveolar basement membranes. This antibody binding triggers complement activation, neutrophil recruitment, and subsequent inflammatory destruction of glomeruli—leading to rapidly progressive glomerulonephritis (RPGN)—and, in ~60% of cases, concurrent diffuse alveolar hemorrhage. Pathogenesis centers on loss of immune tolerance, often precipitated by environmental exposures (e.g., tobacco smoke, hydrocarbon inhalants, viral upper respiratory infections) in genetically susceptible individuals—particularly those carrying HLA-DRB1*15:01 or *15:02 alleles. The disease exhibits a bimodal age distribution: young adults (20–30 years) and older adults (>60 years), with a slight male predominance. Its annual incidence is approximately 0.5–1.0 per million population globally, making it exceptionally rare; prevalence is estimated at 5–10 per million. Risk factors include smoking (strongest modifiable risk), prior respiratory insults (e.g., influenza, vaping), exposure to organic solvents, and certain genetic polymorphisms affecting antigen presentation and B-cell regulation. Notably, anti-GBM disease rarely occurs post-kidney transplantation in patients with prior anti-GBM disease due to recurrence risk. Clinically, patients present acutely with hematuria, proteinuria, rapid decline in eGFR (often progressing to dialysis-dependent kidney failure within days to weeks), fatigue, hypertension, and—when pulmonary involvement exists—cough, dyspnea, hemoptysis, and hypoxemia. Without prompt intervention, mortality exceeds 80%, primarily from respiratory failure or end-stage kidney disease. Even with aggressive therapy, up to 70% of patients require long-term dialysis or kidney transplantation, and 30–40% experience permanent renal impairment. Quality of life is profoundly impacted: patients face chronic fatigue, dietary and fluid restrictions, frequent clinic visits, immunosuppression-related complications (e.g., infections, diabetes, osteoporosis), psychological burden (anxiety, depression), and socioeconomic strain from treatment costs and work disability. Survivors often require lifelong nephrology follow-up, anemia management, cardiovascular risk mitigation, and psychosocial support. Early diagnosis—via serum anti-GBM antibody testing and confirmatory renal biopsy showing linear IgG deposition along GBM—is critical for timely plasma exchange and immunosuppression, which remain the cornerstone of survival and renal preservation.

# 抗GBM肾炎治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用于新诊、血肌酐＜500 μmol/L、无肺出血或透析依赖者。

• •一线免疫抑制：甲泼尼龙冲击（1g/d×3d）+环磷酰胺（0.8–1.2g/m²静滴，每月1次×6月）+血浆置换（PE，1.0–1.5倍血浆体积，隔日1次×14次）

- 血浆置换费：¥1,200–¥1,800/次 × 14次 = ¥16,800–¥25,200 - 必查检验费（ANCA、抗GBM抗体、肾活检病理、eGFR、尿蛋白定量等）：¥2,600–¥3,500

二、手术/介入治疗方案

本病无根治性手术；仅对终末期并发症处理：

• •紧急血液透析建立通路（长期颈内静脉置管或动静脉内瘘成形术）

- 内瘘手术费（含麻醉、耗材）：¥4,200–¥6,800 - 长期透析（非治疗手段，属支持）：¥450–¥650/次 × ≥3次/周

三、特殊复杂/晚期方案

eGFR＜15 mL/min、肺肾双受累、复发/耐药者：

• •利妥昔单抗替代环磷酰胺（375mg/m²×4周）+强化PE+维持激素

• •终末期肾病合并肺出血：需ICU监护+机械通气支持，日均费用¥12,000–¥18,000

四、方案快速选择指南

• •预算有限/初发轻症：选标准PE+激素+CTX（总约¥28,000–¥42,000）
• •中高预算/复发/肺受累：利妥昔单抗方案（总约¥32,000–¥45,000）
• •已透析/晚期：以维持透析+感染防控为主，年均费用¥80,000–¥120,000